Kangchen Pharmaceuticals: The Phase III clinical trial of KC1036 for treating advanced thymic cancer has been approved by the CDE.

Kangchen Pharmaceutical announced that the company's independently developed KC1036 tablets have been approved by the National Medical Products Administration Drug Evaluation Center to conduct pivotal Phase III clinical trials. The study aims to evaluate the efficacy of KC1036 compared to single-agent chemotherapy selected by the researchers in the treatment of advanced recurrent or metastatic thymic cancer that has failed at least one line of platinum-containing chemotherapy in the past. KC1036 is a Class 1 innovative drug developed independently by the company, with strong VEGFR vascular targeting, inhibiting tumor cell growth, and improving the host's anti-tumor immune response by inhibiting AXL. Currently, clinical studies are being conducted on KC1036 for multiple indications including digestive system tumors, thymic tumors, and childhood Ewing's sarcoma, with more than 350 subjects enrolled. Results from Phase II clinical trials have shown that it exhibits outstanding anti-tumor efficacy and controllable safety in advanced recurrent or metastatic thymic cancer.